New Delhi: The Standing Committee on Chemicals & Fertilizers (18th Lok Sabha) has strongly criticised the National Pharmaceutical Pricing Authority (NPPA) and the Department of Pharmaceuticals (DoP) for their failure to establish a "permanent, transparent system" for cost and margin oversight in the pharmaceutical sector, especially for critical drugs. The panel pointed out that while NPPA has the power to cap prices and margins in exceptional cases, long-term price regulation and monitoring of trade margins remain inadequate.

The Committee’s Fourteenth Report, titled “Price Rise of Medicines in the Pharmaceutical Sector Impacting the Lives of Ordinary Citizens – A Review”, highlighted systemic gaps in price regulation and recommended urgent reforms.

Key recommendation on anti-cancer dr

See Full Page